Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.83 |
| ▸ | KIT | P10721 | 1/20 | 0.83 |
| ▸ | FLT4 | P35916 | 1/20 | 0.83 |
| ▸ | KDR | P35968 | 1/20 | 0.83 |
| ▸ | ILK | Q13418 | 1/20 | 0.83 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.83 |
| ▸ | TDO2 | P48775 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039093 | 0.93 | KIT (0.81) | PDGFRBKITFLT4KDRILK | |
| SCHEMBL4035650 | 0.93 | KDR (0.84) | PDGFRBKITFLT4KDRILK | |
| Telatinib SCHEMBL29353813 | 0.91 | KDR (1.00) | PDGFRBKITFLT4KDRILK | |
| Telatinib SCHEMBL29884336 | 0.91 | KDR (1.00) | PDGFRBKITFLT4KDRILK | |
| Telatinib SCHEMBL1250560 | 0.91 | KDR (1.00) | PDGFRBKITFLT4KDRILK | |
| Telatinib SCHEMBL4037375 | 0.90 | KDR (0.98) | PDGFRBKITFLT4KDRILK | |
| Telatinib SCHEMBL4038729 | 0.90 | KDR (0.98) | PDGFRBKITFLT4KDRILK | |
| SCHEMBL4038776 | 0.89 | KDR (0.79) | PDGFRBKITFLT4KDRILK | |
| SCHEMBL4035178 | 0.89 | KIT (0.84) | PDGFRBKITFLT4KDRILK | |
| SCHEMBL4035475 | 0.88 | KDR (0.82) | PDGFRBKITFLT4KDRILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228063-B1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER CORP (US) | 2009-02-11 | — | — | EP | claimed |
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | BAYER HEALTHCARE LLC | 2005-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019424-A1 | Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives | KDR, FLT4, FLT1 | PDGFRB 7/4885KIT 44/4885FLT4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.